Skip to main content
Top
Published in: BMC Nephrology 1/2013

Open Access 01-12-2013 | Research article

Age-dependent parathormone levels and different CKD-MBD treatment practices of dialysis patients in Hungary - results from a nationwide clinical audit

Authors: István Kiss, Zoltán Kiss, Csaba Ambrus, András Szabó, János Szegedi, József Balla, Erzsébet Ladányi, Botond Csiky, Ottó Árkossy, Marietta Török, Sándor Túri, Imre Kulcsár, CKD-MBD Working Group of Hungarian Society of Nephrology

Published in: BMC Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Achieving target levels of laboratory parameters of bone and mineral metabolism in chronic kidney disease (CKD) patients is important but also difficult in those living with end-stage kidney disease. This study aimed to determine if there are age-related differences in chronic kidney disease-mineral and bone disorder (CKD-MBD) characteristics, including treatment practice in Hungarian dialysis patients.

Methods

Data were collected retrospectively from a large cohort of dialysis patients in Hungary. Patients on hemodialysis and peritoneal dialysis were also included. The enrolled patients were allocated into two groups based on their age (<65 years and ≥65 years). Characteristics of the age groups and differences in disease-related (epidemiology, laboratory, and treatment practice) parameters between the groups were analyzed.

Results

A total of 5008 patients were included in the analysis and the mean age was 63.4±14.2 years. A total of 47.2% of patients were women, 32.8% had diabetes, and 11.4% were on peritoneal dialysis. Diabetes (37.9% vs 27.3%), bone disease (42.9% vs 34.1%), and soft tissue calcification (56.3% vs 44.7%) were more prevalent in the older group than the younger group (p<0.001 for all). We found an inverse relationship between age and parathyroid hormone (PTH) levels (p<0.001). Serum PTH levels were lower in patients with diabetes compared with those without diabetes below 80 years (p<0.001). Diabetes and age were independently associated with serum PTH levels (interaction: diabetes × age groups, p=0.138). Older patients were more likely than younger patients to achieve laboratory target ranges for each parameter (Ca: 66.9% vs 62.1%, p<0.001; PO4: 52.6% vs 49.2%, p<0.05; and PTH: 50.6% vs 46.6%, p<0.01), and for combined parameters (19.8% vs 15.8%, p<0.001). Older patients were less likely to receive related medication than younger patients (66.9% vs 79.7%, p<0.001).

Conclusions

The achievement of laboratory target ranges for bone and mineral metabolism and clinical practice in CKD depends on the age of the patients. A greater proportion of older patients met target criteria and received less medication compared with younger patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Moe S, Drüeke T, Cunningham J, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G: Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006, 69: 1945-1953.CrossRefPubMed Moe S, Drüeke T, Cunningham J, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G: Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006, 69: 1945-1953.CrossRefPubMed
2.
go back to reference Rodriguez M, Nemeth E, Martin D: The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol. 2005, 288: F253-F264.CrossRefPubMed Rodriguez M, Nemeth E, Martin D: The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol. 2005, 288: F253-F264.CrossRefPubMed
3.
go back to reference Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC, ARO Investigators: Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011, 26: 1948-1955.CrossRefPubMed Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC, ARO Investigators: Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011, 26: 1948-1955.CrossRefPubMed
4.
go back to reference Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006, 70: 771-780.CrossRefPubMed Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006, 70: 771-780.CrossRefPubMed
5.
go back to reference Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF: Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease. A systematic review and meta-analysis. JAMA. 2011, 305 (11): 1119-1127.CrossRefPubMed Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF: Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease. A systematic review and meta-analysis. JAMA. 2011, 305 (11): 1119-1127.CrossRefPubMed
6.
go back to reference Young EW, Akiba T, Albert J, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M: Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2004, 44 (5 Suppl 2): 34-38.CrossRefPubMed Young EW, Akiba T, Albert J, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M: Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2004, 44 (5 Suppl 2): 34-38.CrossRefPubMed
7.
go back to reference Goodman WG, Goldin J, Kuizon B, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000, 342: 1478-1483.CrossRefPubMed Goodman WG, Goldin J, Kuizon B, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000, 342: 1478-1483.CrossRefPubMed
8.
go back to reference Bro S, Olgaard K: Effects excess PTH on nonclassical target organs. Am J Kidney Dis. 1997, 30: 606-620.CrossRefPubMed Bro S, Olgaard K: Effects excess PTH on nonclassical target organs. Am J Kidney Dis. 1997, 30: 606-620.CrossRefPubMed
9.
go back to reference Szabó A, Mucsi I, Túri S, Kiss I, Poór G: Examination and treatment of renal osteodystrophy (ROD). Hypertonia és Nephrologia. 2007, 11 (5): 217-232. in Hungarian Szabó A, Mucsi I, Túri S, Kiss I, Poór G: Examination and treatment of renal osteodystrophy (ROD). Hypertonia és Nephrologia. 2007, 11 (5): 217-232. in Hungarian
10.
go back to reference Olgard K: Clinical guide to bone and mineral metabolism in CKD. 2006, National Kidney Foundation Olgard K: Clinical guide to bone and mineral metabolism in CKD. 2006, National Kidney Foundation
11.
go back to reference K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003, 42 (4 Suppl 3): 1-201. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003, 42 (4 Suppl 3): 1-201.
12.
go back to reference KDIGO Clinical Practice Guideline for the Diagnosis: Evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009, 76 (Suppl 113): 1-130. KDIGO Clinical Practice Guideline for the Diagnosis: Evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009, 76 (Suppl 113): 1-130.
13.
go back to reference Szabó A, Deák G, Kiss I, Ladányi E, Mucsi I, Tislér A, Török M, Mátyus J, Reusz G, Haris Á, Nagy J, Szegedi J: Examination and treatment of CKD-MBD. Textbook of guidelines of Nephrology. 2011, Medition Publishing Ltd, 1-25. in Hungarian Szabó A, Deák G, Kiss I, Ladányi E, Mucsi I, Tislér A, Török M, Mátyus J, Reusz G, Haris Á, Nagy J, Szegedi J: Examination and treatment of CKD-MBD. Textbook of guidelines of Nephrology. 2011, Medition Publishing Ltd, 1-25. in Hungarian
14.
go back to reference Kiss I, Kiss Z, Szabó A, Szegedi J, Balla J, Ladányi E, Csiky B, Árkossy O, Török M, Túri S, Kulcsár I: Guidelines and clinical practice: clinical audit of CKD-MBD in Hungarian dialyzed patients. Hypertonia és Nephrologia. 2012, 16 (1): 23-30. in Hungarian Kiss I, Kiss Z, Szabó A, Szegedi J, Balla J, Ladányi E, Csiky B, Árkossy O, Török M, Túri S, Kulcsár I: Guidelines and clinical practice: clinical audit of CKD-MBD in Hungarian dialyzed patients. Hypertonia és Nephrologia. 2012, 16 (1): 23-30. in Hungarian
16.
go back to reference Benner D, Nissenson AR, Van Wyck D: Focused clinical campaign improves mineral and bone disorder outcomes. J Ren Care. 2011, 10.1111/j.1755-6686.2011.00233.x. [Epub ahead of print] Benner D, Nissenson AR, Van Wyck D: Focused clinical campaign improves mineral and bone disorder outcomes. J Ren Care. 2011, 10.1111/j.1755-6686.2011.00233.x. [Epub ahead of print]
17.
go back to reference Toussaint ND, Pedagogos E, Beavis J, Becker GJ, Polkinghorne KR, Kerr PG: Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice. Nephrol Dial Transplant. 2011, 26: 1319-1326.CrossRefPubMed Toussaint ND, Pedagogos E, Beavis J, Becker GJ, Polkinghorne KR, Kerr PG: Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice. Nephrol Dial Transplant. 2011, 26: 1319-1326.CrossRefPubMed
18.
go back to reference Ward F, Watson A, Holian J: Chronic kidney disease-mineral and bone disorder (CKD-MBD) management and associated cost in an Irish haemodyalisis cohort. Nephrol Dial Transplant. 2011, 26 (10): 3417-CrossRefPubMed Ward F, Watson A, Holian J: Chronic kidney disease-mineral and bone disorder (CKD-MBD) management and associated cost in an Irish haemodyalisis cohort. Nephrol Dial Transplant. 2011, 26 (10): 3417-CrossRefPubMed
19.
go back to reference Pelletier S, Roth H, Boucher JL, Drueke T, London G, Fouque D, the French Phosphorus and Calcium Observatory investigators: Mineral and bone disease pattern in elderly haemodialysis patients. Nephrol Dial Transplant. 2010, 25: 3062-3070.CrossRefPubMed Pelletier S, Roth H, Boucher JL, Drueke T, London G, Fouque D, the French Phosphorus and Calcium Observatory investigators: Mineral and bone disease pattern in elderly haemodialysis patients. Nephrol Dial Transplant. 2010, 25: 3062-3070.CrossRefPubMed
20.
go back to reference Mucsi I, Hercz G: Adynamic bone disease: pathogenesis, diagnosis and clinical relevance. Curr Opin Nephrol Hypertens. 1997, 6 (4): 356-361.CrossRefPubMed Mucsi I, Hercz G: Adynamic bone disease: pathogenesis, diagnosis and clinical relevance. Curr Opin Nephrol Hypertens. 1997, 6 (4): 356-361.CrossRefPubMed
21.
go back to reference Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C, Fenton S, Sherrard D: Risk factors for renal osteodystrophy: a multivariant analysis. J Bone Miner Res. 1995, 10 (1): 149-156.CrossRefPubMed Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C, Fenton S, Sherrard D: Risk factors for renal osteodystrophy: a multivariant analysis. J Bone Miner Res. 1995, 10 (1): 149-156.CrossRefPubMed
22.
go back to reference Sugimoto T, Ritter C, Morrissey J, Hayes C, Slatopolsky E: Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int. 1990, 37: 1522-1527.CrossRefPubMed Sugimoto T, Ritter C, Morrissey J, Hayes C, Slatopolsky E: Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int. 1990, 37: 1522-1527.CrossRefPubMed
23.
go back to reference Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C, Fenton S, Sherrard D: Renal osteodystrophy in diabetic patients. Kidney Int. 1993, 44 (1): 159-164.CrossRefPubMed Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C, Fenton S, Sherrard D: Renal osteodystrophy in diabetic patients. Kidney Int. 1993, 44 (1): 159-164.CrossRefPubMed
24.
go back to reference Martinez I, Saracho R, Moina I, Montenegro J, Llach F: Is there a lesser hyperparathyroidism in diabetic patients with chronic renal failure?. Nephrol Dial Transplant. 1998, 13 (suppl 3): 9-11.CrossRefPubMed Martinez I, Saracho R, Moina I, Montenegro J, Llach F: Is there a lesser hyperparathyroidism in diabetic patients with chronic renal failure?. Nephrol Dial Transplant. 1998, 13 (suppl 3): 9-11.CrossRefPubMed
25.
go back to reference Fernández-Martín JL, Carrero JJ, Benedik M, Bos WJ, Covic A, Ferreira A, Floege J, Goldsmith D, Gorriz JL, Ketteler M, Kramar R, Locatelli F, London G, Martin PY, Memmos D, Nagy J, Naves-Díaz M, Pavlovic D, Rodríguez-García M, Rutkowski B, Teplan V, Tielemans C, Verbeelen D, Wüthrich RP, Martínez-Camblor P, Cabezas-Rodriguez I, Sánchez-Alvarez JE, Cannata-Andia JB: COSMOS: the dialysis scenario of CKD-MBD in Europe. Nephrol Dial Transplant. 2012, 0: 1-11. 10.1093/ndt/gfs418. Fernández-Martín JL, Carrero JJ, Benedik M, Bos WJ, Covic A, Ferreira A, Floege J, Goldsmith D, Gorriz JL, Ketteler M, Kramar R, Locatelli F, London G, Martin PY, Memmos D, Nagy J, Naves-Díaz M, Pavlovic D, Rodríguez-García M, Rutkowski B, Teplan V, Tielemans C, Verbeelen D, Wüthrich RP, Martínez-Camblor P, Cabezas-Rodriguez I, Sánchez-Alvarez JE, Cannata-Andia JB: COSMOS: the dialysis scenario of CKD-MBD in Europe. Nephrol Dial Transplant. 2012, 0: 1-11. 10.1093/ndt/gfs418.
26.
go back to reference Fukagawa M, Komaba H, Onishi Y, Fukuhara S, Akizawa T, Kurokawa K, MBD-5D Study Group: Mineral metabolism management in haemodialysis patients with secondary hyperparathyroidism in Japan: Baseline data from the MBD-5D. Am J Nephrol. 2011, 33: 427-437.CrossRefPubMed Fukagawa M, Komaba H, Onishi Y, Fukuhara S, Akizawa T, Kurokawa K, MBD-5D Study Group: Mineral metabolism management in haemodialysis patients with secondary hyperparathyroidism in Japan: Baseline data from the MBD-5D. Am J Nephrol. 2011, 33: 427-437.CrossRefPubMed
27.
go back to reference Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW: Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the dialysis outcomes and practice patterns study (DOPPS) DOOPS. J Am Soc Nephrol. 2003, 10: 3270-3277.CrossRef Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW: Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the dialysis outcomes and practice patterns study (DOPPS) DOOPS. J Am Soc Nephrol. 2003, 10: 3270-3277.CrossRef
28.
go back to reference Cannata-Andía JB, Fernández-Martín JL, Zoccali C, London GM, Locatelli F, Ketteler M, Ferreira A, Covic A, Floege J, Górriz JL, Rutkowski B, Memmos DE, Verbeelen D, Tielemans C, Teplan V, Bos WJ, Nagy J, Kramar R, Goldsmith DJ, Martin PY, Wüthrich RP, Pavlovic D, Benedik M: Current management of secondary hyperparathyroidism: multicenter observational study (COSMOS). J Nephrol. 2008, 21: 290-298.PubMed Cannata-Andía JB, Fernández-Martín JL, Zoccali C, London GM, Locatelli F, Ketteler M, Ferreira A, Covic A, Floege J, Górriz JL, Rutkowski B, Memmos DE, Verbeelen D, Tielemans C, Teplan V, Bos WJ, Nagy J, Kramar R, Goldsmith DJ, Martin PY, Wüthrich RP, Pavlovic D, Benedik M: Current management of secondary hyperparathyroidism: multicenter observational study (COSMOS). J Nephrol. 2008, 21: 290-298.PubMed
29.
go back to reference Cannata-Andía JB, Carrera F: The pathophysiology of secondary hyperparathyroidism and the consequencies of uncontrolled mineral metabolism in chronic kidney disease: the role of COSMOS. Nephrol Dial Transplant Plus. 2008, 1 (Suppl 1): 2-6. Cannata-Andía JB, Carrera F: The pathophysiology of secondary hyperparathyroidism and the consequencies of uncontrolled mineral metabolism in chronic kidney disease: the role of COSMOS. Nephrol Dial Transplant Plus. 2008, 1 (Suppl 1): 2-6.
30.
go back to reference Spasovski G, Zdravkovska V, Zabzun M, Antarorov R, Ivanovski K, Janakievska P, Neskovski J, Karceva-Sarajlia E, Panova B, Petrovska T, Zulbeari L, Masin-Spasovska J, Taleska-Matovska N, Gelev S: Achievements in CKD-MBD guidelines targets: is there a progress in the implementation practice?. Int Urol Nephrol. 2012, 44 (6): 1791-828.CrossRefPubMed Spasovski G, Zdravkovska V, Zabzun M, Antarorov R, Ivanovski K, Janakievska P, Neskovski J, Karceva-Sarajlia E, Panova B, Petrovska T, Zulbeari L, Masin-Spasovska J, Taleska-Matovska N, Gelev S: Achievements in CKD-MBD guidelines targets: is there a progress in the implementation practice?. Int Urol Nephrol. 2012, 44 (6): 1791-828.CrossRefPubMed
Metadata
Title
Age-dependent parathormone levels and different CKD-MBD treatment practices of dialysis patients in Hungary - results from a nationwide clinical audit
Authors
István Kiss
Zoltán Kiss
Csaba Ambrus
András Szabó
János Szegedi
József Balla
Erzsébet Ladányi
Botond Csiky
Ottó Árkossy
Marietta Török
Sándor Túri
Imre Kulcsár
CKD-MBD Working Group of Hungarian Society of Nephrology
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2013
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-14-155

Other articles of this Issue 1/2013

BMC Nephrology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.